Is CAR-NK The Natural Successor To CAR-Ts?

 
• By Daniel Chancellor

There is significant commercial potential on offer for the leading CAR-NK developers. While companies committed to continued CAR-T development will need to adapt and innovate in order to remain relevant, especially considering this disruptive new drug class.

Cell regeneration
• Source: Shutterstock

More from Innovation

More from In Vivo